Скачать или смотреть Compassionate Use vs Clinical Trials: What You Need to Know

In this video, we break down the FDA’s Expanded Access Program (EAP) — also known as Compassionate Use — a regulated pathway that allows qualified patients to receive investigational medical products outside of clinical trials.

You’ll learn:
✅ What the Expanded Access Program is and why it exists
✅ Who qualifies and how it differs from clinical trials
✅ How physicians can ethically and legally request investigational drugs or biologics
✅ How to talk with patients about EAP — balancing hope with compliance
✅ Step-by-step guidance for FDA authorization, IRB review, and manufacturer requests

The Expanded Access pathway isn’t about experimental cures — it’s about providing a bridge of hope within ethical and legal frameworks.

This video is designed to help clinicians, researchers, and practice owners understand how to responsibly navigate investigational use within FDA oversight.

Resources Mentioned in This Video:

FDA Expanded Access Program Overview:
https://www.fda.gov/news-events/expan...

Form FDA 3926 (Individual Patient Expanded Access):
https://www.fda.gov/media/98616/download

Expanded Access Navigator (Reagan-Udall Foundation):
https://navigator.reaganudall.org/

Free Mini-Course for Providers, Researchers & Practice Owners:

If you want to learn how to responsibly integrate regenerative and investigational medicine into your practice —

Visit www.regenmedacademy.com to access a free educational mini-course designed for healthcare professionals.

Keywords for Search Optimization:
Expanded Access Program, FDA compassionate use, investigational drug access, FDA Form 3926, regenerative medicine compliance, investigational biologics, compassionate use pathway, FDA oversight for physicians, ethical investigational treatment, Expanded Access for providers, compassionate use education, RegenMed Academy

Disclaimer
This content is for educational purposes only and is not medical, legal, or regulatory advice.
Always consult qualified professionals and refer to official FDA guidance before pursuing any investigational use or Expanded Access request.